TWI729970B - 以抗-vegf darpin治療眼睛病狀之方法 - Google Patents

以抗-vegf darpin治療眼睛病狀之方法 Download PDF

Info

Publication number
TWI729970B
TWI729970B TW103138456A TW103138456A TWI729970B TW I729970 B TWI729970 B TW I729970B TW 103138456 A TW103138456 A TW 103138456A TW 103138456 A TW103138456 A TW 103138456A TW I729970 B TWI729970 B TW I729970B
Authority
TW
Taiwan
Prior art keywords
days
amino acid
binding protein
group
administered
Prior art date
Application number
TW103138456A
Other languages
English (en)
Chinese (zh)
Other versions
TW201609125A (zh
Inventor
湯瑪士 賀曼
貞尼特 茄森
史考特 懷特卡
艾瑞克 利帕
Original Assignee
美商歐樂根公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商歐樂根公司 filed Critical 美商歐樂根公司
Publication of TW201609125A publication Critical patent/TW201609125A/zh
Application granted granted Critical
Publication of TWI729970B publication Critical patent/TWI729970B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW103138456A 2013-11-05 2014-11-05 以抗-vegf darpin治療眼睛病狀之方法 TWI729970B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900246P 2013-11-05 2013-11-05
US61/900,246 2013-11-05
US201462016620P 2014-06-24 2014-06-24
US62/016,620 2014-06-24

Publications (2)

Publication Number Publication Date
TW201609125A TW201609125A (zh) 2016-03-16
TWI729970B true TWI729970B (zh) 2021-06-11

Family

ID=51947485

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103138456A TWI729970B (zh) 2013-11-05 2014-11-05 以抗-vegf darpin治療眼睛病狀之方法

Country Status (14)

Country Link
US (4) US20150126458A1 (enExample)
EP (2) EP3628324A1 (enExample)
JP (3) JP2016536369A (enExample)
KR (1) KR20160070164A (enExample)
CN (1) CN105960247A (enExample)
AU (2) AU2014346921A1 (enExample)
CA (1) CA2927012A1 (enExample)
DK (1) DK3065761T3 (enExample)
ES (1) ES2773317T3 (enExample)
HU (1) HUE047910T2 (enExample)
PL (1) PL3065761T3 (enExample)
PT (1) PT3065761T (enExample)
TW (1) TWI729970B (enExample)
WO (1) WO2015069668A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
US10568934B2 (en) 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
EP3980045A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Recombinant fap binding proteins and their use
IL301762A (en) * 2020-10-07 2023-05-01 Line 6 Biotechnology Inc Methods and materials for the treatment of eye diseases
WO2022074623A1 (en) 2020-10-08 2022-04-14 Notal Vision Ltd. Oct guided therapy
CN114075290B (zh) * 2022-01-20 2022-04-19 南京鼓楼医院 Cd40靶向结合蛋白、其编码核酸以及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4723140B2 (ja) 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
US10568934B2 (en) * 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy

Also Published As

Publication number Publication date
AU2020202968A1 (en) 2020-05-21
PT3065761T (pt) 2020-02-21
JP2016536369A (ja) 2016-11-24
KR20160070164A (ko) 2016-06-17
EP3065761B1 (en) 2020-01-08
EP3628324A1 (en) 2020-04-01
ES2773317T3 (es) 2020-07-10
US20210008158A1 (en) 2021-01-14
AU2014346921A1 (en) 2016-06-02
US20150126458A1 (en) 2015-05-07
US20170157207A1 (en) 2017-06-08
DK3065761T3 (da) 2020-02-17
HUE047910T2 (hu) 2020-05-28
JP2020169191A (ja) 2020-10-15
EP3065761A1 (en) 2016-09-14
CA2927012A1 (en) 2015-05-14
JP2022107628A (ja) 2022-07-22
US20220175881A1 (en) 2022-06-09
TW201609125A (zh) 2016-03-16
PL3065761T3 (pl) 2020-05-18
WO2015069668A1 (en) 2015-05-14
CN105960247A (zh) 2016-09-21

Similar Documents

Publication Publication Date Title
TWI729970B (zh) 以抗-vegf darpin治療眼睛病狀之方法
US20220096596A1 (en) Method of treating amd in patients refractory to anti-vegf therapy
JP6010528B2 (ja) Ｖｅｇｆ−ａレセプターの相互作用を阻害する改変結合タンパク質
KR101698362B1 (ko) Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
HK1179876B (en) Modified binding proteins inhibiting the vegf-a receptor interaction
HK1179876A (en) Modified binding proteins inhibiting the vegf-a receptor interaction

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees